Literature DB >> 3061768

The significance of gastrin in the pathogenesis and therapy of peptic ulcer disease.

C B Lamers1.   

Abstract

Gastrin, a polypeptide hormone secreted by G (gastrin)-cells in the antroduodenal mucosa, is not only a potent stimulant of gastric acid secretion but also exerts trophic actions on the parietal, chief and enterochromaffin-like cells in the oxyntic mucosa. Gastrin plays a crucial role in the pathogenesis of hypergastrinaemic peptic ulcer disease, i.e. in the Zollinger-Ellison syndrome, antral G-cell hyperfunction and retained excluded antrum after subtotal gastrectomy. In patients with normogastrinaemic duodenal ulcer disease the feedback mechanism between gastric acid and gastrin secretion is impaired, while in gastric ulcer patients gastrin secretion is appropriately regulated by gastric acid. Antisecretory drugs may exert varying effects on gastrin secretion. Potent antisecretory drugs, such as omeprazole, increase serum and antral gastrin concentrations, whereas histamine H2-receptor antagonists, such as cimetidine, ranitidine, famotidine and roxatidine, have little influence on gastrin. Interestingly, antisecretory doses of prostaglandin E2-analogues, such as enprostil and arbaprostil [15(R)-15-methylprostaglandin E2], inhibit gastrin secretion, while gastrin is not influenced by prostaglandin E1-analogues, e.g. misoprostol. Somatostatin and the somatostatin-analogue SMS 201-995 reduce serum gastrin levels and gastric acid secretion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3061768     DOI: 10.2165/00003495-198800353-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

1.  The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients.

Authors:  W Peterson; M Feldman; I Taylor; M Bremer
Journal:  Dig Dis Sci       Date:  1979-05       Impact factor: 3.199

Review 2.  Gastrointestinal hormones in the pathogenesis of peptic ulcer disease.

Authors:  I L Taylor
Journal:  Clin Gastroenterol       Date:  1984-05

3.  Influence of chronic omeprazole treatment on gastric endocrine function.

Authors:  H Koop; H Schwarting; A Knorr-Marin; C Willhardt; T Möser; R Arnold
Journal:  Klin Wochenschr       Date:  1987-02-16

4.  Influence of RP 40749 on basal and meal-stimulated serum-gastrin, serum-pepsinogen I, and gastrin-content of the antral mucosa in duodenal ulcer patients.

Authors:  G F Nelis; C B Lamers; G Pals
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

5.  D cell pathology in duodenal ulcers and achlorhydria.

Authors:  J M Polak; S R Bloom; A E Bishop; M V McCrossan
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

6.  Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels.

Authors:  H P Festen; J C Thijs; C B Lamers; J M Jansen; G Pals; R R Frants; J Défize; S G Meuwissen
Journal:  Gastroenterology       Date:  1984-11       Impact factor: 22.682

7.  Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.

Authors:  C B Lambers; T Lind; S Moberg; J B Jansen; L Olbe
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

8.  Effect of pirenzepine on meal-stimulated acid secretion and gastrin release in normal man.

Authors:  M Mignon; J Vatier; P Bauer; S Bonfils
Journal:  Scand J Gastroenterol Suppl       Date:  1982

9.  The effect of selective and non-selective cholinergic blockade on bombesin- and peptone-stimulated gastrin release.

Authors:  J H Kleibeuker; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance.

Authors:  G Williams; H Fuessl; M Kraenzlin; S R Bloom
Journal:  Scand J Gastroenterol Suppl       Date:  1986
View more
  1 in total

1.  Tolerance and rebound to H2-receptor antagonists: intragastric acidity in patients with duodenal ulcer.

Authors:  C H Wilder-Smith; F Halter; H S Merki
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.